Test Price
2,800 AED✅ Home Collection Available
ABCC9 Gene Atrial Fibrillation Type 12 Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Advanced next-generation sequencing (NGS) test for detecting pathogenic variants in the ABCC9 gene associated with familial atrial fibrillation type 12, delivering 99.9% diagnostic sensitivity and specificity.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Mandatory pre-test genetic counseling and telephonic post-test clinical guidance included.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ABCC9 gene encodes the SUR2 subunit of cardiac ATP-sensitive potassium channels; pathogenic variants cause autosomal dominant atrial fibrillation type 12 and are linked to cardiomyopathy. This advanced NGS test delivers definitive molecular diagnosis, guiding personalized management and family screening.
Our laboratory employs Illumina next-generation sequencing with Sanger confirmation for all clinically significant variants, ensuring coverage exceeding 99% of the ABCC9 coding region and splice sites. The analytical sensitivity and specificity exceed 99.9% for single nucleotide variants and small insertions or deletions.
| Feature | Our Test: ABCC9 NGS | Generic Cardiac Gene Panel |
|---|---|---|
| Diagnostic Precision | >99.9% analytical sensitivity & specificity | Variable, often lower depth for ABCC9 |
| Methodology | Illumina NGS + Sanger confirmation | NGS multi-gene, may miss deep intronic variants |
| Turnaround Time | 3–4 Weeks ISO-Certified | 4–8 Weeks typical |
| Genetic Counselling | Mandatory pre- and post-test session included | Often not provided or optional |
Physician Insight & Safety Protocols
Clinical Correlation Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403):
“A positive ABCC9 variant provides critical insight into the molecular basis of early-onset atrial fibrillation, yet it must be interpreted within the full clinical context. I always correlate genetic findings with echocardiographic parameters, Holter monitoring results, and a three-generation pedigree analysis. This integrated approach enables precise risk stratification and informs cascade screening for at-risk family members.”
Important Safety Advisory
Do not discontinue prescribed anticoagulants or antiarrhythmic medications without consulting your treating physician. Abrupt cessation of these therapies may increase the risk of thromboembolic events or arrhythmia recurrence.
Exclusion Criteria & Emergency Red Flags
- Active severe infection or fever; postpone collection until clinically resolved.
- Known bleeding disorder or current anticoagulation with warfarin (INR > 3.0) – please discuss with phlebotomist prior to scheduling.
- If you experience sudden chest pain, severe palpitations, dizziness, or syncope, seek immediate emergency medical attention; do not delay care for genetic testing.
Patient FAQ & Clinical Guidance
1. What is the ABCC9 gene and its role in atrial fibrillation?
The ABCC9 gene provides instructions for making the SUR2 protein subunit of ATP-sensitive potassium channels in cardiac muscle. Specific mutations in ABCC9 alter potassium-ion flow, disrupting the cardiac action potential and predisposing individuals to early-onset familial atrial fibrillation type 12. Identifying the pathogenic variant enables targeted surveillance and personalized treatment planning for affected individuals and their relatives.
2. Who should consider this genetic test?
This test is indicated for individuals with a strong family history of early-onset atrial fibrillation diagnosed before age 60, particularly when multiple first-degree relatives are affected or when cardiomyopathy coexists. Patients with unexplained atrial fibrillation and a pedigree suggestive of autosomal dominant inheritance should undergo mandatory pre-test genetic counseling to fully understand the implications, inheritance patterns, and potential outcomes before testing.
3. How is the ABCC9 genetic test performed?
Following a pre-test genetic counseling teleconsultation, a certified phlebotomist collects a single peripheral blood sample at your preferred location through our VIP mobile phlebotomy service. The specimen is transported under temperature-controlled cold-chain conditions to our ISO 9001:2015 accredited laboratory. DNA extraction is followed by targeted enrichment and Illumina next-generation sequencing covering the entire ABCC9 coding region and flanking splice sites, with Sanger confirmation of all clinically significant findings. Results are reported within 3 to 4 weeks, accompanied by a post-test clinical guidance call.
4. What do the results mean for my family members?
If a pathogenic or likely pathogenic ABCC9 variant is identified, first-degree relatives have a 50% chance of inheriting the same variant under autosomal dominant inheritance. Predictive testing for asymptomatic adult relatives is available following genetic counseling. A negative result in a relative with a known familial variant generally excludes the familial risk, while a positive result triggers early clinical surveillance including periodic ECG and echocardiography, enabling timely intervention and improved outcomes.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the following UAE legislative frameworks governing genetic testing, data protection, and clinical safety:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Ensures your genetic data is processed lawfully, stored securely, and never shared without explicit consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Governs the secure handling and transmission of electronic health records and genomic data across digital platforms.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Establishes the legal framework for clinical responsibility, patient safety, and informed consent in all diagnostic procedures.
All genetic testing services adhere to DHA Standards for Genetic Testing and Counseling, ensuring that pre-test counseling, informed consent, and post-test result disclosure meet international best practices.
Clinical & Logistical Metadata
| Test Name | ABCC9 Gene Sequencing – Familial Atrial Fibrillation Type 12 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) |
| Methodology Used | Next-Generation Sequencing (Illumina) + Sanger Confirmation, ISO 9001:2015 Accredited |
| ICD-10-CM Code | I48.0, I48.1, I48.2, I48.3, I48.4, I48.91 |
| LOINC Code | 81269-7 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians